HC Wainwright Weighs in on AnaptysBio FY2030 Earnings

Key Points

• HC Wainwright issued a bullish long‑term forecast, projecting FY2030 EPS of $7.67 and maintaining a Buy rating with a $66 target, which contrasts with the current consensus full‑year estimate of (‑$6.08).
• AnaptysBio beat Q4 estimates, reporting EPS of $1.58 versus $0.89 expected and revenue of $108.3M versus $87.1M, a performance that has helped drive multiple analyst price‑target upgrades.
• Management announced a planned spin‑off of its biopharma portfolio targeted for Q2 2026 and the board authorized a $100M stock buyback (about 9.6% of shares), while insiders have been net sellers in recent months.

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Stock analysts at HC Wainwright issued their FY2030 EPS estimates for shares of AnaptysBio in a research note issued to investors on Wednesday, March 4th. HC Wainwright analyst E. Bodnar anticipates that the biotechnology company will earn $7.67 per share for the year. HC Wainwright currently has a "Buy" rating and a $66.00 target price on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share.

Several other research analysts also recently commented on the stock. Truist Financial raised their price objective on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a "hold" rating in a report on Monday, November 10th. Guggenheim restated a "buy" rating on shares of AnaptysBio in a research report on Thursday, December 18th. Stifel Nicolaus raised their target price on shares of AnaptysBio from $56.00 to $85.00 and gave the stock a "buy" rating in a report on Thursday. Weiss Ratings reissued a "sell (d-)" rating on shares of AnaptysBio in a research note on Wednesday, January 21st. Finally, Wells Fargo & Company lifted their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an "overweight" rating in a report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $71.89.

AnaptysBio Stock Down 1.0%

AnaptysBio stock traded down $0.58 during mid-day trading on Thursday, reaching $59.97. 193,325 shares of the company's stock were exchanged, compared to its average volume of 470,587. The firm has a market capitalization of $1.66 billion, a PE ratio of -115.32 and a beta of 0.32. AnaptysBio has a one year low of $15.32 and a one year high of $63.47. The business's fifty day simple moving average is $50.02 and its 200 day simple moving average is $38.65.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Monday, March 9th. The biotechnology company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $0.89 by $0.69. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.The business had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million.

Institutional Trading of AnaptysBio

Hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC lifted its holdings in AnaptysBio by 153.3% in the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company's stock valued at $558,000 after acquiring an additional 18,165 shares during the last quarter. Savant Capital LLC acquired a new position in shares of AnaptysBio in the 2nd quarter valued at $241,000. Los Angeles Capital Management LLC acquired a new position in shares of AnaptysBio in the 2nd quarter valued at $334,000. Creative Planning lifted its position in AnaptysBio by 26.9% in the second quarter. Creative Planning now owns 16,854 shares of the biotechnology company's stock valued at $374,000 after buying an additional 3,571 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in AnaptysBio during the second quarter worth about $240,000.

Insider Transactions at AnaptysBio

In other AnaptysBio news, CFO Dennis Mulroy sold 2,515 shares of the firm's stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $112,445.65. Following the completion of the sale, the chief financial officer directly owned 21,852 shares of the company's stock, valued at $977,002.92. This trade represents a 10.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric J. Loumeau sold 10,000 shares of AnaptysBio stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $54.00, for a total value of $540,000.00. Following the transaction, the insider owned 12,835 shares in the company, valued at approximately $693,090. This represents a 43.79% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 156,280 shares of company stock valued at $7,254,939. 33.50% of the stock is currently owned by company insiders.

AnaptysBio announced that its board has authorized a stock buyback plan on Friday, November 21st that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the biotechnology company to buy up to 9.6% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board believes its shares are undervalued.

More AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target sharply to $85 and reiterated a Buy rating, implying meaningful upside versus recent levels — a notable institutional upshift that can attract buyers and support the rally. Stifel Raises PT to $85
• Positive Sentiment: HC Wainwright boosted its target to $66 (Buy) and published a very bullish FY2030 EPS projection (~$7.67), signaling strong analyst conviction about longer‑term earnings potential. Analyst upgrades like this add momentum. H.C. Wainwright PT Raise & Estimates
• Positive Sentiment: Barclays nudged its target to $79 with an Overweight rating — another institutional signal supporting demand for the shares. Barclays Raises PT to $79
• Positive Sentiment: Q4 results beat expectations: EPS $1.58 vs. $0.89 est., and revenue $108.3M vs. $87.1M est. The upside to both top and bottom line reduces near‑term execution risk and helps justify higher analyst targets. Q4 Earnings Beat
• Positive Sentiment: Management confirmed the planned spin‑off of its biopharma portfolio into a new public company, “First Tracks Biotherapeutics,” targeted for Q2 2026. A separation can unlock value by letting each business be valued on its own merits. Spin‑off Announcement
• Positive Sentiment: GSK’s Jemperli reported strong commercial performance (Q4 growth), and Anaptys highlighted expected royalty upside — management sees >$390M annualized royalties to Anaptys at peak GSK guidance, which supports longer‑term revenue visibility. Jemperli Royalty Outlook
• Neutral Sentiment: Reports show short interest figures as effectively zero/unchanged — likely a data anomaly and not a meaningful driver of price action. Short Interest Data
• Negative Sentiment: Despite the beat, the company still reports a negative net margin and negative return on equity, and consensus models expect losses in the near term (previous consensus for the fiscal year was negative EPS). These fundamentals are a reminder of inherent biotech execution and commercialization risk. Q4 Release & Financials

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.